immunotherapy

Over a decade ago, a disastrous trial killed research on a potential immunotherapy. Can a Regeneron bispecific revive it?
Over a decade ago, a disastrous trial killed research on a potential immunotherapy. Can a Regeneron bispecific revive it?
Endpoints
immunotherapy
Regeneron
clinical trials
bispecific antibodies
Flag link:
Early survival data boost Ziopharm's 'controlled IL-12' immunotherapy for glioblastoma
Early survival data boost Ziopharm's 'controlled IL-12' immunotherapy for glioblastoma
Endpoints
Ziopharm Oncology
Ad-RTS-hIL-12
immunotherapy
glioblastoma
Flag link:
Roche signs up with Oncimmune to explore immunotherapy responses
Roche signs up with Oncimmune to explore immunotherapy responses
Pharmaforum
Roche
Oncimmune
autoantibodies
immunotherapy
Flag link:
Affinivax announces $120m Series B financing to advance pipeline of novel MAPS vaccines and immunotherapies
Affinivax announces $120m Series B financing to advance pipeline of novel MAPS vaccines and immunotherapies
Pharmaceutical Business Review
Affinivax
vaccines
MAPS
immunotherapy
Flag link:
BeiGene reports positive Phase III interim analysis for lung cancer drug
BeiGene reports positive Phase III interim analysis for lung cancer drug
MedCity News
BeiGene
clinical trials
immunotherapy
lung cancer
tislelizumab
non-squamous non-small cell lung cancer
Flag link:
Sanofi beat out 3 suitors and one last-minute bid in its pricey $2.5B Synthorx buyout
Sanofi beat out 3 suitors and one last-minute bid in its pricey $2.5B Synthorx buyout
Fierce Pharma
Sanofi
Synthorx
M&A
immunotherapy
Flag link:
Novartis, Bayer, Longwood back genomics startup to speed search for immunotherapy targets
Novartis, Bayer, Longwood back genomics startup to speed search for immunotherapy targets
Endpoints
Novartis
Bayer
Longwood
immunotherapy
genomics
immuno-oncology
Flag link:
Bone Tumors Stop Immunotherapy Working For Prostate Cancer
Bone Tumors Stop Immunotherapy Working For Prostate Cancer
Forbes
immunotherapy
prostate cancer
bone tumors
Flag link:
Editas and Celgene sub Juno are tackling hottest immunotherapy cells
Editas and Celgene sub Juno are tackling hottest immunotherapy cells
Endpoints
Editas Medicine
Celgene
Juno Therapeutics
CRISPR
gene editing
immunotherapy
Flag link:
Working on the Next Generation of Immuno-Oncology Therapies
Working on the Next Generation of Immuno-Oncology Therapies
BioSpace
immuno-oncology
immunotherapy
Washington University School of Medicine
Flag link:
Verseau launches with $50m to develop first-in-class macrophage-targeted immunotherapies
Verseau launches with $50m to develop first-in-class macrophage-targeted immunotherapies
Pharmaceutical Business Review
Verseau Therpeutics
macrophages
immunotherapy
Flag link:
Lilly cancer drug pipeline hit by trial setback
Lilly cancer drug pipeline hit by trial setback
Biopharma Dive
Eli Lilly
pegilodecakin
immunotherapy
pancreatic cancer
ARMO BioSciences
Flag link:
Pushing to Improve Immunotherapies, Arcellx Raises $85 Million in Series B
Pushing to Improve Immunotherapies, Arcellx Raises $85 Million in Series B
BioSpace
Arcellx
immunotherapy
Flag link:
Moderna pens mRNA immunotherapy pact with Harvard
Moderna pens mRNA immunotherapy pact with Harvard
Fierce Biotech
Moderna Therapeutics
MRNA
immunotherapy
Harvard
Flag link:
Tactiva Therapeutics — A Biotech Startup Focusing on the Future of Immunotherapy
Tactiva Therapeutics — A Biotech Startup Focusing on the Future of Immunotherapy
Persimmon Development
Tactiva Therapeutics
startups
biotech
immunotherapy
Flag link:
In a small study, a cancer vaccine assist beats immunotherapy drugs alone
In a small study, a cancer vaccine assist beats immunotherapy drugs alone
Stat
cancer vaccines
vaccines
Neon Therapeutics
cancer
metastatic non-small-cell lung cancer
metastatic bladder cancer
immunotherapy
Flag link:
Are Natural Killer Cells the Next Big Thing in Immunotherapy?
Are Natural Killer Cells the Next Big Thing in Immunotherapy?
Motley Fool
immunotherapy
NK immunotherapies
CAR-T
Flag link:
Provention’s Teplizumab Can Delay Onset of Type 1 Diabetes, Trial Results Show
Provention’s Teplizumab Can Delay Onset of Type 1 Diabetes, Trial Results Show
BioSpace
Povention Bio
clinical trials
type 1 diabetes
ADA
immunotherapy
Flag link:
ASCO 2019: The Long Game, Targeted Pills, First-Ever Buzz & More
ASCO 2019: The Long Game, Targeted Pills, First-Ever Buzz & More
Xconomy
ASCO 2019
cancer
immunotherapy
diagnostics
Veracyte
Grail
Moderna Therapeutics
Amgen
Nektar Therapeutics
Blueprint Medicines
Merck
AstraZeneca
Roche
breast cancer
Flag link:
The entrepreneur behind the cancer immunotherapy revolution
The entrepreneur behind the cancer immunotherapy revolution
Stat
cancer
immunotherapy
Nils Longberg
Flag link:

Pages